期刊文献+

他汀类药物对新发房颤的治疗效果与CHADS2评分的关系分析 被引量:2

Relationship between CHADS2 score and statins for the treatment of new-onset atrial fibrillation
下载PDF
导出
摘要 目的 探讨CHADS2评分与新发房颤是否存在关系,及CHADS2评分是否可以运用到他汀类药物对急性心肌梗死患者心律失常的预防.方法 选取213例急性心肌梗死患者,根据CHADS2评分分为3组,其中A组61例患者的CHADS2评分为0分,B组83例患者的CHADS2评分为1-2分,C组69例患者的CHADS2评分为3-6分.对所有患者均使用他汀类和非他汀类药物治疗,观察他汀类药物的治疗效果与CHADS2评分之间的关系.结果 CHADS2评分越高的急性心肌梗死患者的新发房颤发病率越高(P<0.05);CHADS2评分≤2的急性心肌梗死患者服用他汀类药物后,新发房颤的发病率远低于未服用他汀类药物的患者(P<0.05),而CHADS2评分≥3的患者中,他汀类药物则不存在此效果(P >0.05);CHADS2评分≤2的急性心肌梗死患者服用他汀类药物后,C反应蛋白的水平远低于未服用他汀类药物的患者(P<0.05),而CHADS2评分≥3的患者中,他汀类药物则不存在此效果(P>0.05).结论 CHADS2评分能够很好地预测新发房颤的发病率,并且其还能很好地评价他汀类药物对急性心肌梗死心律失常患者的预防效果. Objective To investigate the relationship between CHADS2 score and new-onset atrial fibrillation, and whether the CHADS2 score can be applied to evaluate the preventive effect of statins on the arrhythrnia of acute myocardial infarction. Methods 213 cases of acute myocardial infarction patients were selected and divided into 3 groups according to CHADS2 score. Group A had 61 patients with CHADS2 score of 0 point,group B had 83 cases of patients with CHADS2 score of 1 - 2 point, group C had 69 patients with CHADS2 score of 3 - 6 point. All patients were treated with statin and nonstain, and the relationship between the therapeutic effect of statin and CHADS2 score was observed. Results The higher was CHADS2 score in patients with acute myocardial infarction, the higher was the incidence of new onset atrial fibrillation( P 〈0. 05 ) ;after taking statins ,the incidence of new-onset atrial fibrillation of acute myocardial infarction patients with CHADS2 score was less than or equal to 2, far lower than patients without taking statins(P 〈0. 05) ;neither the patients with CHADS2 score greater than or equal to 3 taking statins,nor the effect had significant difference( P 〈 0.05 ) ;after taking statins, the C-reactive protein levels of acute myocardial infarction patients with CHADS2 score was less than or equal to 2, far lower than the patients without taking statins ( P 〈 0. 05 ) ; while the patients with CHADS2 score greater than or equal to 3 had no similar result ( P 〉 0.05 ). Conclusion CHADS2 score can predict the incidence of new-onset atrial fibrillation, and it is also a good evaluation of statins in cu- ring acute myocardial infarction patients with arrhythmias.
作者 刘海燕
出处 《实用药物与临床》 CAS 2014年第8期955-958,共4页 Practical Pharmacy and Clinical Remedies
关键词 急性心肌梗死 新发房颤 CHADS2评分 他汀类药物 Acute myocardial infarction New onset atrial fibrillation CHADS2 score Statins
  • 相关文献

参考文献20

  • 1Jabre P,Jouven X,Adent F,et al.Atrial fibrillation and death aftermyocardial infarction:a community study[J].Circulation,2011(19):2094-2100.
  • 2Wann LS,Curtis AB,January CT,et al.2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation(updating the 2006 guideline):A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].Circulation,2011(123):104-123.
  • 3Schmitt J,Duray G,Gersh BJ,et al.Atrial fibrillation in acute myocardial infarction:a systematic review of the incidence,clinical features and prognostic implications[J].Eur Heart J,2009(30):1038-1045.
  • 4安瑗,王慧媛,赵志刚,陈晓红.他汀类药物的临床合理应用[J].实用药物与临床,2011,14(5):408-411. 被引量:17
  • 5Han Z,Yanmin Y,Jun Z,et al.Prognostic value of admission heart rate in patients with ST-segment elevation myocardial infarction:Role of Type 2 diabetes mellitus[J].BMC cardiovascular disorders,2012(1):104-107.
  • 6Cortes-Bergoderi M,Pineda AM,Santana O.The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductaseinhibitors in gastrointestinal tract disorders:a comprehensive review[J].J Gastrointestin Liver Dis,2013,22(2):199-204.
  • 7Hodis HN,Mack WJ.The timing hypothesis and hormone replacement therapy:a paradigm shift in the primary prevention of coronary heart disease in women[J].J Am Geriatr Soc,2013,61(6):1011-1018.
  • 8Asanin M,Stankovic S,Mrdovic I,et al.B-type natriuretic peptide predicts new-onset atrial fibrillation in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention[J].Peptides,2012(1):74-77.
  • 9连雯雯,郝丽英.钙通道在心房颤动时表达及功能变化的研究进展[J].实用药物与临床,2013,16(2):151-154. 被引量:4
  • 10Chao TF,Liu CJ,Chen SJ,et al.CHADS(2)score and risk of new-onset atrial fibrillation:A nationwide cohort study in Taiwan[J].Int J Cardiol,2012(24):421-436.

二级参考文献77

  • 1商丽华,胡大一,赵秀丽,张仁汉.普伐他汀对快速起搏心房肌结构重构的影响[J].中华心律失常学杂志,2004,8(3):172-176. 被引量:21
  • 2郭继鸿,刘元生,张海澄,李学斌,许原,张幼怡,袁兰.心房颤动犬心房肌细胞三磷酸肌醇受体和兰尼碱受体的表达及功能改变[J].中华医学杂志,2004,84(14):1196-1199. 被引量:9
  • 3Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:346
  • 4仝其广,胡大一.他汀类药物的安全性问题[J].中国实用内科杂志,2007,27(9):655-657. 被引量:64
  • 5Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J, 2<XXi, 27: 949-953.
  • 6Wolf P A, Abbott RD, Kannel \VB. Atrial fibrillation as an independent risk factor for stroke: the FIlIIIlingJam Study. Stroke, 1991,22: 983-988.
  • 7Hannon N, Sheehan 0, Kelly L, et al. Stroke associated with atrial fibrillation-incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis, 2010, 29: 43-49.
  • 8Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007,146: 857-867.
  • 9van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta?analysis. JAMA, 2002, 288: 2441-2448.
  • 10Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ, 1995,311: 1356-1359.

共引文献29

同被引文献25

  • 1胡晓锋.Association between CHADS_2 score and long-term atrial fibrillation recurrence rate after catheter ablation[J].China Medical Abstracts(Internal Medicine),2014,31(3):162-162. 被引量:1
  • 2Briasoulis A, Tousoulis D, Bakogiannis C, et al. Novel anti- platelet agents for the treatment of stable angina pectoris [J]. Curr Pharm Des,2013,19(9) : 1581-1586.
  • 3Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology [J]. J Thromb Haemost,2005, 3(8) : 1800-1814.
  • 4Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction :a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial [J]. Lancet,2012,380 (9850) : 1317-1324.
  • 5Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes [J]. N Engl J Med, 2012,366( 1 ) : 20-33.
  • 6Serebruany VL, Miller M, Pokov AN, et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS study) [J]. Am J Cardiol,2006,97(9):1332-1336.
  • 7Gharacholou SM, Lopes RD, Washarn JB, et al. Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician [Jl- J Thromb Thrombolysis,2010,29(4):516- 528.
  • 8Weitz JI. Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome [J]. Thromb Haemost, 2014,112 (5) : 924-931.
  • 9Cirino G, Severino B. Thrombin receptors and their antagonists: an update on the patent literature [J]. Expert Opin Ther Pat, 2010,20(7) : 875-884.
  • 10Zhang P, Gruber A, Kasuda S, et al. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell- penetrating PAR1 pepducin [J]. Circulation,2012,126 (1) : 83-91.

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部